Clinical trials: Trauma Coagulopathy
- Condition Trauma Coagulopathy
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acquired Bleeding Disorder, Trauma
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
This trial is conducted in Africa, Asia, Europe, Oceania and North America. The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII given in conjunction with standard therapy in the treatment…
- Trial name
- NCT01563523
- Testing
- activated recombinant human factor VII
- Where
- 9 sites in Australia, Austria and 7 more
- Volunteers
- 283 people
- Sponsor
- Novo Nordisk A/S
Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage
HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency
The objective of the Expanded Access Program is to provide HEMOLEVEN, a replacement coagulation factor XI, to patients with severe inherited factor XI deficiency where, in the opinion of the treating physician, the benefits of…
- Conditions
- Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
- Trial name
- EAP (NCT01701947)
- Testing
- Hemoleven
- Where
- United States
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies